Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects

• Dose-escalation study of single oral administration of Methosulide in healthy adults to assess the safety and tolerability.
• Multiple-dose study of Methosulide in healthy adults to assess the safety and tolerability.
• Dose-escalation study of single oral administration of Methosulide in healthy adults to evaluate the pharmacokinetic characteristics
• Multiple-dose study of Methosulide in healthy adults to evaluate the pharmacokinetics characteristics
• Single dose,and cross-over study of Methosulide in healthy adults to evaluate the pharmacokinetic characteristics and effect of food.

Inclusion criteria

• Male or female, between 18 and 45 years of age, Body Mass Index (BMI) between 19～25 kg/m2, Weight > or = 50kg
• In good health as judged by the investigator
• Without history of medication within 2 weeks before the test
• Non-allergic constitution, without known drug allergy
• Without history of major organ diseases
• Without other factors affecting drug metabolism, such as smoking (within 2 weeks), drinking (within 2 weeks), or drug abuse history
• Signed informed consent form and Fully understood the contents, process and possible adverse reactions of the test

Exclusion criteria

• History of kinds of food or drug allergy, or suffering from allergic diseases or allergic constitution
• Presence (in screening stage) or history of the acute/chronic organic diseases or clinical manifestations: blood system, renal disease, endocrine system, respiratory system, digestive system, cardiovascular system, nervous system, mental disease, allergic diseases (including drug allergy, but not including non-treatment, asymptomatic, seasonal allergy during the period of oral administration)
• History of abuse of Smoking, alcohol, or other drugs
• Severe hemorrhage factors to affect the venous blood collection
• Severe blood loss or blood donation within 3 months before the test
• Participation in other drug trials within 3 months before the test
• Usage of drugs known to have damage to the main organs within 3 months before the test
• Without good compliance, or unable to match with the test
• with a clinically significant abnormality in routine serological detection: including Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infected
• For childbearing-aged women only, usage of any hormonal contraceptive methods within 3 months before the drug administration; or unable or unwilling to use non-hormonal contraceptive methods to contraception from the day of dosing until 14 days after dosing
• Be otherwise unsuitable for the study, in the opinion of the Investigator.